2016-11-18
Interim Report for Kancera AB (publ) Q3 2016, January 1 – September 30, 2016
The period January to September 2016 in brief R&D expenses for the period amounted to SEK 13.3m (SEK 12.1m) of which the third quarter constituted SEK 4.6m (SEK 3.2m). Operating income for the period amounted to SEK -15.8m (SEK...
Read More